Ischemia Reperfusion Injury Therapeutics Market, by Indication (Heart Injury, Kidney Injury, Intestine Injury, and Other Injury), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and Others), and by Region (North America, Latin America, Eu

Ischemia Reperfusion Injury Therapeutics Market, by Indication (Heart Injury, Kidney Injury, Intestine Injury, and Other Injury), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Ischemia reperfusion injury (IRI), also known as reoxygenation injury, is tissue damage that arises when blood supply returns to the tissue (reperfusion) after a period of lack of oxygen (ischemia). The symptoms of ischemia injury include bradycardia, headache, hypertension, and seizures.
Market Dynamics
The increase in the number of tissue damage cases and the growing awareness about treatment of reperfusion injury are major factors boosting growth of the global ischemia reperfusion therapeutics market. Moreover, introduction of novel drugs for treatment of complications related to ischemia reperfusion, and the rising research & development activities are propelling the market growth. For instance, in November 2021, Faraday Pharmaceuticals announced positive top-line results from the phase II trial of FDY-5301 for ischemia reperfusion injury therapeutics treatment.
Moreover, factors such as the rising incidence of ischemic reperfusion injury across the globe, and strategic acquisitions of key players for developing novel treatment are expected to favor growth of the market during the period of forecast.
Key features of the study:
This report provides in-depth analysis of the global ischemia reperfusion injury therapeutics market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
The study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
It profiles key players in the global ischemia reperfusion injury therapeutics market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, key developments, and strategies
Key players covered as a part of this study are Omeros Corporation, Nyken B.V., Opsona Therapeutics Limited, Pharming Group N.V., Orexo AB, PledPharma AB, Proteo, Inc., Prolong Pharmaceuticals, Prothix BV, Zealand Pharma A/S, Stealth BioTherapeutics Inc., Amyndas Pharmaceuticals LLC, Antipodean Pharmaceuticals, Inc., Angion Biomedica Corp., Bayer AG, Bolder Biotechnology, Inc., Biomedica Management Corporation, Curatis Pharma GmbH, Erimos Pharmaceuticals, LLC, Ensemble Therapeutics Corporation, and Gilead Sciences, Inc.
Insights from this report would allow marketers and management authorities of companies to make an informed decision with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The global ischemia reperfusion injury therapeutics market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers in the global ischemia reperfusion therapeutics market, research and consulting firms, new entrants, and financial analysts.

Detailed Segmentation:
Global Ischemia Reperfusion Injury Therapeutics Market, By Indication:
Heart Injury
Kidney Injury
Intestine Injury
Other Injury
Global Ischemia Reperfusion Injury Therapeutics Market, By Distribution Channel:
Retail Pharmacies
Hospital Pharmacies
Others
Global Ischemia Reperfusion Injury Therapeutics Market, By Region:
North America
By Country:
U.S.
Canada
By Indication:
Heart Injury
Kidney Injury
Intestine Injury
Other Injury
By Distribution Channel:
Retail Pharmacies
Hospital Pharmacies
Others
Europe
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
By Indication:
Heart Injury
Kidney Injury
Intestine Injury
Other Injury
By Distribution Channel:
Retail Pharmacies
Hospital Pharmacies
Others
Asia Pacific
By Country:
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
By Indication:
Heart Injury
Kidney Injury
Intestine Injury
Other Injury
By Distribution Channel:
Retail Pharmacies
Hospital Pharmacies
Others
Latin America
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
By Indication:
Heart Injury
Kidney Injury
Intestine Injury
Other Injury
By Distribution Channel:
Retail Pharmacies
Hospital Pharmacies
Others
Middle East
By Country:
GCC
Israel
Rest of Middle East
By Indication:
Heart Injury
Kidney Injury
Intestine Injury
Other Injury
By Distribution Channel:
Retail Pharmacies
Hospital Pharmacies
Others
Africa
By Country/Region:
South Africa
Central Africa
North Africa
By Indication:
Heart Injury
Kidney Injury
Intestine Injury
Other Injury
By Distribution Channel:
Retail Pharmacies
Hospital Pharmacies
Others
Company Profiles
Omeros Corporation
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Nyken B.V.
Opsona Therapeutics Limited
Pharming Group N.V.
Orexo AB
PledPharma AB
Proteo, Inc.
Prolong Pharmaceuticals
Prothix BV
Zealand Pharma A/S
Stealth BioTherapeutics Inc.
Amyndas Pharmaceuticals LLC
Antipodean Pharmaceuticals, Inc.
Angion Biomedica Corp.
Bayer AG
Bolder Biotechnology, Inc.
Biomedica Management Corporation
Curatis Pharma GmbH
Erimos Pharmaceuticals, LLC
Ensemble Therapeutics Corporation
Gilead Sciences, Inc.
“*” marked represents similar segmentation in other categories in the respective section.